Somatostatin secretion from pancreatic δ-cells is a Ca^2+^-dependent process involving influx of extracellular Ca^2+^ and mobilization of intracellular Ca^2+\ [@R5]^. Mechanistic studies of the metabolic regulation of somatostatin secretion are complicated by the scarcity of δ-cells within the pancreatic islets (approx. 5%)^[@R1]^. To study the role of intracellular Ca^2+^ in the regulation of somatostatin (Sst) secretion from δ-cells, we used mice expressing the genetically encoded Ca^2+^ sensor GCaMP3 in Sst-expressing cells (Sst-Cre-GCaMP3 mice^[@R7]^).These mice exhibited normal gross characteristics, glucose homeostasis and pancreatic islet hormone release ([Supplementary Fig. 1a-f](#SD1){ref-type="supplementary-material"}). Expression of GCaMP3 was confined to the δ-cells ([Supplementary Fig. 2a-c](#SD1){ref-type="supplementary-material"}). GCaMP3-positive cells had high expression of key δ-cell genes such as the intracellular Ca^2+^ release channels RyR3 and InsP~3~ as well as the plasmalemmal voltage-gated R- and T-type Ca^2+^ channels ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Of the glucose transporters, δ-cells expressed particularly high levels of *Glut1* but low expression of *Sglt1* and *Sglt2* was also detected.

We correlated Sst release and δ-cell cytoplasmic Ca^2+^ (\[Ca^2+^\]~i~) in Sst-Cre-GCaMP3 islets. Three examples of recordings of \[Ca^2+^\]~i~ in individual δ-cells within intact pancreatic islets are shown in [Fig. 1a](#F1){ref-type="fig"}. The glucose responsiveness was variable: spontaneous \[Ca^2+^\]~i~ oscillations were observed in 27±3% of the cells at 1 mM glucose, which increased to 48±7% (p\<0.05 vs 1 mM) at 4 mM and 82±5% at 20 mM glucose (p\<0.001 vs 1 mM; 79 cells in 7 islets from 7 mice). Increasing glucose from 1 to 4 and 20 mM stimulated Sst release by 100% and 1000%, respectively ([Fig. 1b](#F1){ref-type="fig"}), responses that were associated with comparable increases in the frequency of the \[Ca^2+^\]~i~ oscillations ([Fig. 1c](#F1){ref-type="fig"}). When applied at 1 mM glucose, the K~ATP~ channel blocker tolbutamide (0.2 mM) produced a 5-fold increase in the frequency of the \[Ca^2+^\]~i~ oscillations ([Fig. 1d](#F1){ref-type="fig"} and [Extended Data 1a](#F5){ref-type="fig"}). Conversely, the K~ATP~ channel activator diazoxide and the L- and R-type Ca^2+^ channel blockers isradipine and SNX-482, respectively, abolished or reduced glucose-induced \[Ca^2+^\]~i~ oscillations in most δ-cells and strongly inhibited Sst secretion ([Fig. 1e-g](#F1){ref-type="fig"} and [Extended Data 1](#F5){ref-type="fig"} and [2](#F6){ref-type="fig"}). Sst secretion involves intracellular Ca^2+^ release by a mechanism sensitive to ryanodine and thapsigargin^[@R8]^ ([Extended Data 2a](#F6){ref-type="fig"}). The inhibitory effect of thapsigargin on Sst secretion correlated with an average 40% decrease in the frequency of the \[Ca^2+^\]~i~ oscillations ([Extended Data 2e](#F6){ref-type="fig"}).

To distinguish between entry of extracellular Ca^2+^ and intracellular Ca^2+^ release in driving the glucose-induced \[Ca^2+^\]~i~ response, we performed parallel measurements of \[Ca^2+^\]~i~ and membrane potential in superficial δ-cells within intact islets ([Fig. 2a](#F2){ref-type="fig"}). Increasing glucose resulted in membrane depolarization and initiation of action potential firing. Large \[Ca^2+^\]~i~ oscillations preceded the initiation of electrical activity and action potential firing was in fact associated with only small increases in \[Ca^2+^\]~i~. Increasing glucose also induced \[Ca^2+^\]~i~ oscillations in δ-cells voltage-clamped at -70 mV ([Fig. 2b](#F2){ref-type="fig"}), an experimental paradigm leading to the abolition of spontaneous electrical activity. Although the glucose-induced \[Ca^2+^\]~i~ oscillations observed in voltage-clamped cells cannot result from action potential firing, they were strongly inhibited (fully or partially) by diazoxide ([Fig. 2b](#F2){ref-type="fig"}, inset).

How can glucose induce \[Ca^2+^\]~i~ oscillations in hyperpolarised/voltage-clamped δ-cells and why are they suppressed by diazoxide? Diazoxide inhibits glucose-induced action potential firing and secretion in the β-cell^[@R9]^. We therefore hypothesized that paracrine factors (such as insulin^[@R10]^ or urocortin-3^[@R11]^) released in response to electrical activity in neighbouring (unclamped) β-cells underlie the \[Ca^2+^\]~i~ oscillations in voltage-clamped δ-cells. This scenario is supported by the finding that the suppression of glucose-induced \[Ca^2+^\]~i~ oscillations by diazoxide was reversed in some δ-cells by addition of [exogenous]{.ul} insulin (17% of δ-cells; [Fig. 2c *i*](#F2){ref-type="fig"}) or urocortin-3 (9% of δ-cells; [Fig. 2c *ii*](#F2){ref-type="fig"}). To restore intracellular cAMP levels in the δ-cells that may have decreased following diazoxide-induced inhibition of glucagon^[@R12]^ and urocortin-3 release (both of which act by promoting cAMP production), we also tested the effects of insulin in the presence of 3 μM of forskolin. In the presence of this adenylate cyclase activator, insulin more robustly induced \[Ca^2+^\]~i~ oscillations (27% of δ-cells; [Fig. 2c *iii*](#F2){ref-type="fig"}; p=0.048 vs. no forskolin by χ^2^). In the presence of forskolin, spontaneous \[Ca^2+^\]~i~ oscillations were observed in some δ-cells even before addition of insulin and the frequency of these oscillations was much higher in the simultaneous presence of insulin and forskolin than in the presence of insulin alone (0.6 min^-1^ vs 0.12 min^-1^; p=0.01). Insulin's capacity to induce \[Ca^2+^\]~i~ oscillations in δ-cells was antagonised by dapagliflozin (an inhibitor of sodium-glucose co-transporter 2, SGLT2) in 85% of insulin-responsive cells ([Fig. 2c, *iii-iv*](#F2){ref-type="fig"}). It was ascertained separately that forskolin-induced stimulation of Sst secretion was not affected by dapagliflozin in mouse and human islets ([Extended Data 3a-b](#F7){ref-type="fig"}).

The effect of insulin on \[Ca^2+^\]~i~ in δ-cells correlated with stimulation of Sst release: diazoxide reduced glucose-induced Sst release by 80%, an effect reversed by application of exogenous insulin ([Fig. 2d](#F2){ref-type="fig"}). Dapagliflozin abolished the stimulatory effect of exogenous insulin on Sst secretion in the presence of glucose and diazoxide ([Fig. 2d](#F2){ref-type="fig"}). Although Sst release in the presence of insulin, diazoxide and glucose was not statistically lower than in islets exposed to 20 mM glucose alone (p=0.16), the mean value was 30% lower. This might reflect the component of Sst secretion resulting from δ-cell electrical activity ^[@R13]^ and/or urocortin-3 ^[@R11]^.

We next examined the role of [endogenous]{.ul} insulin (i.e. that released from β-cells within the islets) on Sst secretion using islets from mice lacking insulin receptors in Sst-expressing cells (SIRKO mice^[@R14]^). Glucose-stimulated Sst secretion was 50% weaker in the insulin receptor-deficient islets than in control islets ([Fig. 2e](#F2){ref-type="fig"}), an effect recapitulated by the insulin receptor antagonist S961 ([Extended Data 3c-d](#F7){ref-type="fig"}). Dapagliflozin reduced glucose-induced Sst secretion by 70% in wild-type islets under control conditions. Sst secretion in wild-type islets in the simultaneous presence of 20 mM glucose and dapagliflozin was not statistically different (p\<0.16) from that in SIRKO islets exposed to 20 mM glucose alone. Dapagliflozin reduced somatostatin secretion in SIRKO islets but this effect did not attain statistical significance (p=0.06).

In islets exposed to 20 mM glucose, dapagliflozin inhibited Sst release with an IC~50~ of 10 nM ([Fig. 2f](#F2){ref-type="fig"}). The effects of phlorizin (50 μM) on glucose-induced Sst secretion were similar to those of high concentrations of dapagliflozin ([Fig. 2g](#F2){ref-type="fig"}). Part of the stimulatory effect of glucose on Sst secretion was resistant to both dapagliflozin and phlorizin, presumably reflecting the stimulation mediated by K~ATP~ channel closure. Indeed, Sst secretion in the presence of glucose and phlorizin was not higher than that elicited by 0.3 mM tolbutamide (p=0.33; [Fig. 2g](#F2){ref-type="fig"}). Sst secretion elicited by this high concentration of tolbutamide (40x the K~i~ for the inhibitory effect on K~ATP~ channels^[@R9]^) is only 20% of that produced by 20 mM glucose, reinforcing previous arguments that depolarization as such is a weak stimulus of Sst secretion^[@R8]^.

In wild-type islets exposed to 20 mM glucose, glucagon secretion was reduced by 52% compared to that observed at 1 mM glucose ([Fig. 2h](#F2){ref-type="fig"}). This inhibitory effect was reversed by addition of either the Sst receptor 2 (SSTR2) antagonist CYN154806 or dapagliflozin. The combination of CYN154806 and dapagliflozin produced greater stimulation of glucagon secretion than dapagliflozin alone (p\<0.01). Neither dapagliflozin nor CYN154806 affected glucagon or Sst secretion at 1 mM glucose ([Extended Data 4a-b](#F8){ref-type="fig"}).

How does dapagliflozin inhibit Sst secretion? Electrical activity and elevation of \[Ca^2+^\]~i~ mediated glucose-induced Sst secretion. The effects of dapagliflozin on glucose-induced δ-cell electrical activity ([Extended Data 4c](#F8){ref-type="fig"}) and \[Ca^2+^\]~i~ increases were inconsistent ([Extended Data 5a-b](#F9){ref-type="fig"}).

There is functional and immunocytochemical evidence for the presence of SGLT2 in δ-cells^[@R10]^. To specifically activate the SGLT-expressing δ-cells, we used the non-metabolisable SGLT-specific substrate methyl-α-D-glucopyranoside (αMDG)^[@R15]^. When tested at 1 mM glucose, addition of αMDG (19 mM) stimulated Sst secretion, albeit less strongly than a corresponding increase in glucose ([Fig. 2i](#F2){ref-type="fig"}). This stimulatory effect of αMDG on Sst secretion was associated with the occurrence of \[Ca^2+^\]~i~ oscillations in 37% of the δ-cells ([Fig. 3a](#F3){ref-type="fig"}) without stimulation of δ-cell electrical activity ([Extended Data 4d](#F8){ref-type="fig"}), suggesting they reflect intracellular Ca^2+^ release. In keeping with this idea, treatment of islets with thapsigargin largely abolished αMDG's capacity to increase \[Ca^2+^\]~i~ (p\<0.001 compared to no thapsigargin by χ^2^; [Fig. 3b](#F3){ref-type="fig"}).

SGLTs mediate the uptake of glucose/αMDG by co-transport with Na^+^ down its electrochemical gradient. We explored the significance of the transmembrane Na^+^ gradient for the effects of αMDG on δ-cell \[Ca^2+^\]~i~ by lowering the extracellular Na^+^ concentration (\[Na^+^\]~o~) from the normal 140 mM to 10 mM. This reduced both the αMDG-induced \[Ca^2+^\]~i~ oscillations ([Fig. 3a](#F3){ref-type="fig"}) and αMDG- and glucose-induced Sst secretion ([Fig. 2i](#F2){ref-type="fig"}). The inhibitory effect of Na^+^ removal on glucose-induced Sst secretion was comparable to that produced by dapagliflozin in control islets (*cf*. [Fig. 2e](#F2){ref-type="fig"}). Addition of αMDG increased \[Na^+^\]~i~ in 39% of the δ-cells ([Fig. 3c-d](#F3){ref-type="fig"} and [Extended Data 4e](#F8){ref-type="fig"}), in agreement with the fraction of δ-cells in which \[Ca^2+^\]~i~ oscillations were induced by αMDG (37%; see above). When αMDG was applied in the presence of 100 nM dapagliflozin, the increase in \[Na^+^\]~i~ was abolished ([Fig. 3c-d](#F3){ref-type="fig"}). Dapagliflozin (1 nM-1 μM) also prevented the insulin-dependent potentiation of the αMDG-induced increase in \[Na^+^\]~i~ ([Fig 3e-f](#F3){ref-type="fig"} and [Extended Data 6](#F10){ref-type="fig"}).

We hypothesised that the increase in \[Na^+^\]~i~ triggers CICR by producing a small increase in \[Ca^2+^\]~i~. This idea is supported by our finding that application of the Na^+^ ionophore monensin initiated \[Ca^2+^\]~i~ oscillations ([Fig. 3g](#F3){ref-type="fig"}). The oscillations evoked by monensin persisted for \>30 min and were resistant to a cocktail of diazoxide and the Ca^2+^ channel blockers isradipine and SNX482 ([Fig. 3g](#F3){ref-type="fig"} and [Extended Data 7a](#F11){ref-type="fig"}) and independent of electrical activity ([Fig. 3b](#F3){ref-type="fig"} and [Extended Data 7b](#F11){ref-type="fig"}).

Lowering \[K^+^\]~o~ inhibits the plasmalemmal Na^+^/K^+^ pump^[@R16]^ and it is therefore expected to increase \[Na^+^\]~i~. Insulin's hypokalaemic (i.e. reduction of plasma K^+^) action is well established and has been attributed to stimulation of K^+^ uptake in skeletal muscle^[@R17]^. In mice, insulin (0.75 U/kg) lowered plasma \[K^+^\] from 5.0±0.7 to 3.0±0.3 mM ([Fig. 3h](#F3){ref-type="fig"}), comparable to that reported in patients with type 1 diabetes^[@R6]^. Notably, plasma \[K^+^\] fell to values \<4 mM in all mice and \<2.7 mM in 3 of 5 mice. Lowering \[K^+^\]~o~ to 2.7 mM increased \[Na^+^\]~i~ in δ-cells ([Fig. 3i-j](#F3){ref-type="fig"}). This increase in \[Na^+^\]~o~ was associated with the induction of \[Ca^2+^\]~i~ oscillations in 72% of δ-cells in islets exposed to 1 mM glucose ([Fig. 3k](#F3){ref-type="fig"}).

At 1 mM glucose, δ-cells are hyperpolarized and do not generate action potentials. Reducing \[K^+^\]~o~ to 1.7 mM promptly produced an additional 7±1 mV hyperpolarization (n=3: measured 5 min after switching to the lower \[K^+^\]~o~). The resting membrane potential of the δ-cell is determined by K~ATP~ channel activity^[@R18]^ and depends on \[K^+^\]~o~ ([Extended Data 7d](#F11){ref-type="fig"}). We determined the effect of reduced \[K^+^\]~o~ on glucagon and Sst secretion. Despite its hyperpolarising effect, lowering \[K^+^\]~o~ from 4.7 mM to 3.7 mM stimulated Sst secretion in islets exposed to 6 mM glucose; no further stimulation was observed at 2.7 or 1.7 mM ([Fig. 4a](#F4){ref-type="fig"}). A stimulatory effect was also observed at 1 mM glucose but in this case a reduction to ≤2.7 mM was required ([Fig. 4a](#F4){ref-type="fig"}). The stimulation of Sst secretion was associated with progressive inhibition of glucagon secretion at both 1 and 6 mM ([Fig. 4b](#F4){ref-type="fig"}). We found that CYN154806 reversed the inhibitory effect of 1.7 mM \[K^+^\]~o~ at both 1 mM or 6 mM glucose ([Fig. 4c](#F4){ref-type="fig"}). Thus, the insulin-induced reductions of plasma K^+^ are likely to be associated with stimulation of Sst secretion under both normoglycaemic (6 mM) and severely 'hypoglycaemic' (1 mM) conditions *in vitro*.

Type-2 diabetes (T2DM) is associated with impaired glucose-induced insulin secretion and dysregulation of glucagon secretion^[@R12],[@R19]^ but whether Sst secretion is also affected is not known. We studied Sst and glucagon in hyperglycaemic Fh1βKO mice, a model of progressive β-cell failure associated with marked suppression of glucagon secretion^[@R20]^. In control islets, Sst secretion at 1 mM glucose was low and stimulated \>10-fold at 20 mM glucose. In islets from hyperglycaemic Fh1βKO mice, Sst secretion at 1 mM glucose was increased 6-fold compared to control islets (echoing previous observations in diabetic dogs and rats^[@R21],[@R22]^) and 20 mM glucose was without a statistically significant stimulatory effect ([Fig. 4d](#F4){ref-type="fig"}). This correlated with a \>75% reduction of glucagon secretion at 1 mM glucose (p\<0.05; [Fig. 4e](#F4){ref-type="fig"}). Consistent with an increased Sst tone at 1 mM glucose, addition of CYN154806 increased glucagon secretion by 143±11% in Fh1βKO mice but only 13±14% in controls (p=0.022).

We extended these data to human islets. In islets from non-diabetic donors (ND), Sst secretion was low at 1 mM glucose and stimulated \>3-fold by 20 mM glucose ([Fig. 4f](#F4){ref-type="fig"}). In contrast, glucose was without stimulatory effect in islets from donors with T2DM. Interestingly, there was a trend (p\<0.06) towards elevated Sst release at 1 mM glucose, similar to that observed in Fh1βKO islets. There was no difference in Sst content in islets from diabetic and non-diabetic donors ([Extended Data 8a](#F12){ref-type="fig"}). In T2DM islets, glucagon secretion at 1 mM glucose was on average 65% lower than observed in ND preparations ([Fig. 4g](#F4){ref-type="fig"}), despite glucagon content was 200% higher in T2DM islets ([Extended Data 8b](#F12){ref-type="fig"}). We tested whether Sst receptor antagonists can restore glucagon secretion at low glucose in a small number of human T2DM islet preparations. We found that the SSTR2 antagonist CYN154806 increased glucagon secretion at 1 mM glucose in two preparations with low glucagon secretion. In a third preparation with higher glucagon secretion, CYN154806 had no effect ([Fig. 4h](#F4){ref-type="fig"}). Extrapolating from our findings in islets from mice we propose that the stimulatory effect of the SSTR2 antagonist in T2DM islets reflects hypersecretion of Sst at low glucose concentrations. This conclusion is reinforced by electrophysiological measurements in intact human pancreatic islets demonstrating transient and CYN154806-sensitive membrane hyperpolarizations in T2DM but not in ND α-cells ([Extended Data 8c-e](#F12){ref-type="fig"}).

The schematic in [Fig. 4i](#F4){ref-type="fig"} combines these findings into a model for glucose-induced Sst secretion that incorporates K~ATP~ channels, the Na^+^/K^+^ pump, voltage-gated Ca^2+^ channels and intracellular Ca^2+^-induced Ca^2+^ release (CICR). Glucose- and insulin-dependent Na^+^ uptake is sufficient to trigger CICR and Sst secretion in δ-cells even in the absence of electrical activity. The effects of dapagliflozin in δ-cells were observed at 1-10 nM, concentrations adequate to suppress SGLT2 activity but too low to inhibit SGLT1^[@R23]^. However, the expression of *Slc5a2* (which encodes SGLT2) is low in mouse δ-cells and that of *Slc5a1* (encoding SGLT1) is higher (although still lower than transcripts encoding GLUT1-3; see [Supplementary Table 1](#SD1){ref-type="supplementary-material"} and ^[@R24]^). The low expression of SGLT1/2 would be in agreement with the small size of the current (\~1 pA) in δ-cells inhibited by high (μM) concentrations of dapagliflozin^[@R14]^. In kidney cells, insulin selectively activates SGLT2 (via an effect involving protein phosphorylation) with little effect on SGLT1^[@R25]^ but it remains possible that SGLT1 is insulin-sensitive in δ-cells. Dapagliflozin has been reported to stimulate glucagon secretion both *in vitro*^[@R26]^ and *in vivo*^[@R27]^ (but see ^[@R24]^). Our data suggest that the stimulation of glucagon secretion is secondary to the suppression of Sst secretion, resulting in removal of paracrine suppression of α-cells. Given the low expression of *Slc5a2* in δ-cells, the possibility that the dapagliflozin-induced suppression of Sst secretion reflects an off-target SGLT2-independent effect remains possible, similar to what was recently reported for the related compound canagliflozin^[@R28]^. Ultimately, to conclusively demonstrate that SGLT1 or 2 are functional in δ-cells, studies would need to be conducted using δ-cell-specific ablation of *Slc5a1* and/or *Slc5a2*.

Despite the uncertainty about the molecular identity of the transporter mediating Na^+^ and glucose uptake into δ-cells, it is clear that the mechanisms involved culminate in elevation of \[Na^+^\]~i~, which accounts for the Na^+^-dependent ability of the non-metabolisable glucose analogue αMDG to evoke \[Ca^2+^\]~i~ oscillations and Sst release by promoting CICR, in agreement with previously reported stimulatory effects of 3-O-methyl-D-glucose on Sst secretion^[@R29]^. It is notable that inhibition of the plasmalemmal Na^+^/Ca^2+^ (NCX) by reduction of \[Na^+^\]~o~ leads to a reduction of Ca^2+^ in δ-cells (i.e. the opposite to what we observe and unlike the increase seen in β-cells^[@R30]^). We therefore propose that the αMDG/glucose-induced increase \[Na^+^\]~i~ is mediated by activation of intracellular Na^+^/Ca^2+^ exchange (like NCLX^[@R31]^) rather than inhibition of NCX. The resulting small/initial increase in δ-cell \[Ca^2+^\]~i~ thus produced leads to further mobilization of Ca^2+^ from intracellular stores (including the sER) by activation of CICR, explaining why the effect of αMDG on \[Ca^2+^\]~i~ was almost abolished after pretreatment with thapsigargin. The model explains why glucose is a stronger stimulus of Sst secretion than αMDG. Unlike αMDG, which exclusively acts by increasing \[Na^+^\]~i~, glucose also causes K~ATP~ channel closure. Thus, elevation of \[Na^+^\]~i~ represents one important intracellular messenger -- but not the only one - linking elevated plasma glucose to stimulation of Sst secretion.

Our findings suggest that exogenous insulin may not only lead to hypoglycaemia by stimulating glucose uptake but also interfere with the defences against hypoglycaemia by producing hypokalaemia by stimulation of Sst secretion (via inhibition of the Na-K pump and elevation of \[Na^+^\]~i~) and suppression of glucagon secretion. It is intriguing that the effects of T2DM on Sst secretion resemble those produced by lowering of \[K^+^\]~o~: namely increased basal Sst secretion and impaired stimulation by high glucose. Our data raise the interesting possibility that SGLT2 inhibitors -- regardless of their exact mode of action - may correct the Sst secretion defects associated with diabetes, thereby restoring counter-regulatory glucagon secretion and reducing the risk of fatal hypoglycaemia^[@R4]^.

Materials and Methods {#S1}
=====================

Ethics {#S2}
------

All animal experiments were conducted in accordance with the UK Animals Scientific Procedures Act (1986) and ethical guidelines of the universities of Oxford, Lund and Gothenburg and were approved by the respective local Ethical Committees. Human pancreatic islets were isolated, with ethical approval and clinical consent, at the Diabetes Research and Wellness Foundation Human islet Isolation Facility (Oxford) and the Alberta Diabetes Institute IsletCore (Edmonton, Canada). Details on the donors are provided in [Supplementary Table 2](#SD1){ref-type="supplementary-material"}.

Mouse models {#S3}
------------

In this study, mice expressing GCaMP3 and/or RFP under the Sst promoter (Sst-Cre-GCaMP3 and Sst-Cre-RFP mice, respectively) were used. These mice were generated as previously described^[@R32]^. The generation of mice lacking insulin receptors in Sst-secreting δ-cells (SIRKO mice) have been reported elsewhere^[@R14]^. Fh1βKO mice were generated as previously described^[@R33]^.

Intraperitoneal glucose tolerance test {#S4}
--------------------------------------

Blood glucose levels were measured using the Accu-Check Aviva from a drop of blood obtained by a tail vein nick. For these experiments, 12-20 weeks old mice were used. Mice were fed ad libitum and fed blood glucose levels were measured prior to fasting. For the GCaMP3 experiments, mice were fasted overnight (16 h). A bolus of glucose (2g per kg of body weight, Sigma) was injected intraperitoneally (ip) with a 25-gauge needle at time 0. Blood glucose levels were measured at intervals of 0, 15, 30, 60, 90, 120 and 150 min after ip glucose administration.

Plasma K^+^ measurements {#S5}
------------------------

Plasma K^+^ concentrations were measured with a micro-ion potassium selective electrode (LIS-146KCM), micro reference electrode (LIS DJM146) and a 6230N Ion meter (Lazar Research Laboratories, Inc., USA). K^+^ standard solutions were prepared by diluting 0.1 M standard KCl to concentrations between 0.1 and 100 mM KCl. Both the K^+^ and reference electrodes were placed in the standard solutions and the voltage determined. The K^+^ and references electrodes were washed and wiped between each measurement. The insulin tolerance tests were performed in C57Bl6j mice. Blood samples were obtained at t=0 and t=45 min after injection of insulin. The blood cells were removed and plasma frozen pending later analysis. Plasma samples were diluted 20x to a final volume of 100 μl and injected into clean well plates and measurements were conducted as above.

Pancreatic islets isolation {#S6}
---------------------------

Mice (16-24 weeks old) were killed by cervical dislocation, the pancreases quickly removed and islets isolated either by collagenase (Sigma) or liberase (Roche) digestion.

Immunocytochemistry {#S7}
-------------------

Immunocytochemistry was performed as previously described^[@R14]^. The primary antibodies used in this study were: rabbit anti-somatostatin (Sigma, 1:250), Guinea pig anti-insulin (Sigma, 1:3000), mouse anti-glucagon (Sigma, 1:4000), chicken anti-GFP (Invitrogen, 1:500). The secondary antibodies were all from Invitrogen (1:500).

Flow cytometry of islet cells (FACS) {#S8}
------------------------------------

Pancreatic islets from Sst-Cre-GCaMP3 mice were dissociated into single cells by trypsin digestion and mechanical dissociation as described previously^[@R14]^ and filtered through a 30 μm filter to remove remaining clumps of cells.

Single cells were passed through a MoFlo Legacy (Beckman Coulter). GCaMP3- or RFP-positive cells were purified by combining several narrow gates ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). Forward and side scatter were used to isolate small cells and to exclude cell debris. Cells were then gated on pulse width to exclude doublets or triplets. GCaMP3-positive cells were excited with a 488 nm laser and the fluorescent signal was detected through a 530/40 nm bandpass filter (*i.e*. in the range 510-550 nm). RFP was excited with the 488 nm laser and the fluorescent signal was detected through a 580/30 nm bandpass filter (*i.e*. in the range 565-595nm). GCaMP3- or RFP-negative cells were collected in parallel.

RNA extraction, cDNA synthesis and quantitative PCR {#S9}
---------------------------------------------------

The levels of gene expression in the positive and in the negative FAC-sorted fractions were determined using real-time quantitative PCR (qPCR). Total RNA was extracted using RNeasy Micro Kit (Qiagen) and cDNA was synthesised using High Capacity RNA-to-cDNA™ Kit (Applied Biosystem).

qPCR was performed using SYBR Green kit (QuantiFast SYBR Green PCR Kit, Qiagen) and ABI 7900HT Sequence Detection System (Applied Biosystems). Primers used were QuantiTect Primer Assays: QT00114289 (Ins2), QT00124033 (Gcg), QT00239295 (Sst), QT00095242 (Actb). Each sample was run in duplicate or triplicate. Differences in expression of target genes in the GCaMP3 positive/negative were calculated using the 2^**Δ-ΔCT**^ method^[@R34]^.

Secretion measurements {#S10}
----------------------

Freshly isolated islets were used in static secretion experiments. These experiments were performed as described previously^[@R10]^.

Two different extracellular solutions (ES) were used for the various experiments: ES1 contained (mM) 120 NaCl, 4.7 KCl, 2.5 CaCl~2~, 25 NaHCO~3~, 1.2 KH~2~PO~4~, 1.2 MgSO~4~, 10 HEPES and 0.1% BSA (pH=7.4 with NaOH and bubbled with 95:5% O~2~:CO~2~). For some experiments (to allow correlation with electrophysiology and \[Ca^2+^\]~i~ imaging when 'bubbling' with O~2~:CO~2~ is not feasible), a modified extracellular medium (ES2) that equilibrates with atmospheric CO~2~ levels was used. It consisted of (mM) 140 NaCl, 4.7 KCl, 2 NaHCO~3~, 0.5 NaH~2~PO~4~, 0.5 MgSO~4~, 5 HEPES, 1.5-2.6 CaCl~2~ (EC1) and 0.1% BSA (pH=7.4 with NaOH). Secretion data obtained with the two different media were essentially identical.

All experiments were carried out in a shaking water bath at 37ºC. Groups of 15-20 islets from at least three mice were pooled together and used in each experiment. When extracellular \[Na^+^\] was lowered to 10 mM, the extracellular solution was compensated with choline chloride to maintain iso-osmolarity.

All chemicals used in this study were from Sigma (UK) with the following exception: isradipine and SNX-482 were from Alomone (Jerusalem, Israel); ryanodine, thapsigargin and CYN154806 were from Tocris (Abingdon, UK) and dapagliflozin was from Cayman Bioscience (Cambridge, UK). S961 was from Sigma-Aldrich.

Samples were assayed by radioimmunoassay (RIA). The kits for glucagon and somatostatin were from Millipore (USA) and Eurodiagnostica (Malmö, Sweden), respectively. The somatostatin RIA from Eurodiagnostica was discontinued and two series of experiments ([Fig. 2f-g](#F2){ref-type="fig"}) were instead analysed using a RIA from Diasource (P/N RB306RUO; Louvain-la-Neuve, Belgium). The assay provided by the latter supplier indicated higher basal (1 mM glucose) Sst release and this may be the reason that the fold stimulation produced by glucose is lower in these experiments.

For unknown reasons, glucagon secretion rates vary between different laboratories and/or assays. Human glucagon secretion data reported here include only experiments performed in Oxford. This is the explanation why glucagon secretion at 1 mM glucose now reported is lower than that presented in a previous study (which included experiments conducted in two different laboratories)^[@R12]^. Because the experiments were performed in two different laboratories and over many years, secretion data have been expressed relative glucagon or somatostatin secretion at 1 mM glucose.

Pancreas perfusion {#S11}
------------------

*In situ* measurements of glucagon secretion were performed using the perfused mouse pancreas. Briefly, the aorta was ligated above the coeliac artery and below the superior mesenteric artery and then cannulated. The pancreas was perfused with KRB containing glucose and CYN154806 at a speed of 0.24 ml/min using an Ismatec Reglo Digital MS2/12 peristaltic pump. The perfusate was maintained at 37°C using a Warner Instruments temperature control unit TC-32 4B in conjunction with a tube heater (Warner Instruments P/N 64-0102) and a Harvard Apparatus heated rodent operating table. The effluent was collected in intervals of 1 min. Samples were subsequently stored at -80°C. Glucagon content in perfusate were measured using U-plex glucagon ELISA (Meso Scale Discovery), according to the manufacturer's protocol.

Intracellular \[Ca^2+^\] measurements {#S12}
-------------------------------------

\[Ca^2+^\]~i~ measurements were performed as described previously^[@R35]^. Islets were imaged in a heated chamber at 37ºC placed on an inverted LSM510 confocal microscope (Zeiss; Oberkochen, Germany) using a 40X oil objective (NA1.4). The pinhole diameter was kept constant, and frames of 256x256 pixels were taken every 1-3 s.

Parallel measurement of membrane potential and \[Ca^2+^\]~i~ {#S13}
------------------------------------------------------------

The electrophysiological measurements were performed in intact islets essentially using the perforated-patch whole-cell technique in the voltage- or current-clamp modes in δ-cells.

Parallel measurements of \[Ca^2+^\]~i~ and membrane potential were performed using an Axioskop 2FS microscope (Zeiss, Oberkochen, Germany) equipped with a 40x/0.8 objective, Lambda DG-4 exciter (Sutter Instruments, USA) and Orca-R2 cooled CCD camera (Hamamatsu, Japan). Images were acquired using an open-source Micromanager software (developed at Ron Vale's lab, UCSF, San Francisco, USA) and processed using ImageJ. Data analysis was performed in Igor Pro (Wavemetrics).

Intracellular Na^+^ and pH measurements {#S14}
---------------------------------------

Time-lapse imaging of \[Na^+^\]~i~ in dispersed mouse islets was performed on a Zeiss Axiozoom.V16 microscope. Cells were pre-loaded with 6 μM of Sodium Green (Molecular Probes) for 30 min at room temperature and imaged at several locations simultaneously. Sodium Green was excited at 490 nm and emission was collected at 515 nm, using a CCD camera. Time-lapse images were collected every 60 s and the bath solution was superfused at 60 μl/min, at 34°C. δ-cells were identified by the RFP fluorescence. Images were acquired using ZenBlue software (Carl Zeiss). Imaging of pH~i~ in GCamP3-expressing δ-cells was performed on an inverted Zeiss AxioVert 200 microscope equipped with Zeiss 510-META laser confocal scanning system, using 40x/1.3 objective. Cells were loaded with 6 μM of the pH-sensitive dye SNARF-5F for 50 min at room temperature. SNARF-5F was excited at 543 nm and emission was collected at 650 nm and 600 nm.

Statistical analysis {#S15}
--------------------

Calcium imaging videos were analysed using a combination of Fiji and IgorPro. Briefly, an in-house macro was used to auto-detect GCaMP3-expressing regions of interest representing individual δ-cells. The mean fluorescent intensities of these regions of interest were exported to IgorPro for individual wave plotting of each δ-cell. The mean fluorescent intensities were expressed as F/F~0~ and transformed using a Mexican hat filter and Fourier scaling for baseline correction. AUC and spike frequency detection methods in IgorPro were then employed to quantify these parameters for each δ-cell. The AUC and spike frequency data were compared back to the raw traces visualised in Fiji to confirm accuracy and faithful representation of the raw data.

GraphPad Prism 6.0 software was used for statistical analysis. Differences between two groups were assessed by two-tailed unpaired Student's *t*-test while for differences between more groups one-way ANOVA or two-way ANOVA followed by a post hoc test were used. Data are presented as mean values ± S.E.M.

Extended Data {#S16}
=============

![*a-d***,** Effect of tolbutamide (*a*), diazoxide (*b*), isradipine (*c*) and SNX482 (*d*) on \[Ca^2+^\]~i~ in δ-cells in islet exposed to 1 (*a*) or 20 mM glucose (*b-d*). Compounds were added as indicated by horizontal lines.](EMS85189-f005){#F5}

![*a*, Somatostatin secretion at 1 or 20 mM glucose and at 20 mM glucose plus 10μM thapsigargin, Data represent 4 experiments per conditions using islets from 3 mice. Statistical significances were determined by one-way ANOVA followed by Tukey's post hoc. \*\*p\<0.005 *vs* 1 mM glucose; †p\<0.05 *vs*. 20 mM glucose. b, As in (*a*) but testing the effects of the R-type Ca^2+^ channel blocker SNX-482 and L-type Ca^2+^ channel blocker isradipine. \*\*\*p\<0.001 vs 1 mM glucose; ††p\<0.005 and †p\<0.05 vs 20 mM glucose. Experiments (n=4, 5 or 6) from 3 mice. *c-d*, Representative recordings of \[Ca^2+^\]~i~ at 20 mM glucose alone (*c*) or 20 mM glucose plus thapsigargin (*d*) as indicated. *e*, Effects of thapsigargin on the frequency of \[Ca^2+^\]~i~ oscillations recorded at 20 mM glucose in experiments of the type displayed in (*c-d*). Data are derived from n=68 cells in 3 different islets isolated from 3 different mice. Statistical significances were evaluated by one-way ANOVA followed by Tukey's post hoc. \*p\<0.05 vs 20 mM glucose alone. All data are represented as mean ± SEM.](EMS85189-f006){#F6}

![*a-b*, Somatostatin secretion from (*a*) mouse and (*b*) human islets at 4 mM glucose in the presence and absence of forskolin and dapagliflozin as indicated. Data are based on 4 experiments from 8 mice and n=4 experiments from 4 human donors run in at least quadruplicate (n\>16). Statistical significances were determined by one-way ANOVA followed by Tukey's post hoc. Data have been normalised to somatostatin secretion at 4 mM glucose. \*p\<0.05; \*\*\*p\<0.001; ns=not significant (p=0.78). *c-d*, Insulin (c) and somatostatin secretion (*d*) at 1 and 20 mM glucose in the absence and presence of the insulin receptor antagonist S961 as indicated. Data are based on n=10 experiments using islets from 4 mice. Statistical significances were determined by one-way ANOVA followed by Tukey's post hoc. Data have been normalised to secretion at 1 mM glucose. \*\*\*p\<0.001 vs 1 mM glucose; ††p\<0.01 vs 20mM glucose. All data are represented as mean ± SEM.](EMS85189-f007){#F7}

![*a*, Glucagon secretion in the presence of 1 mM glucose, dapagliflozin and CYN154806 as indicated (n=6, n=9 experiments/3 mice). Glucagon secretion has been normalised to responses at 1 mM glucose. *b*, Somatostatin secretion in the presence of glucose, dapagliflozin and CYN154806 as indicated (n=6, n=9 experiments/3 mice). Secretion has been normalised to responses at 1 mM glucose. Statistical significances were determined by one-way ANOVA followed by Tukey's post hoc. \*\*\*p\<0.001 vs 1 mM glucose; †††p\<0.001 vs 20mM; ‡‡p\<0.01 20 mM glucose, dapagliflozin and CYN154806 vs 20 mM glucose and CYN154806 alone. *c*, Effects of dapagliflozin on δ-cell electrical activity recorded from δ-cells in intact islets exposed to 20 mM glucose. In 2 out of 4 cells, dapagliflozin repolarized the δ-cell and suppressed electrical activity whereas it was without effect in the remaining 2 cells (islets from 4 different mice). *d*, Failure of 19 mM αMDG to evoke electrical activity in δ-cells exposed to 1 mM glucose. Measurements are representative of 7 different cells in islets from 4 different mice. *e*, Sodium Green fluorescence (heatmap) measured in 40 different δ-cells from 4 different mice simultaneously. Each line represents an individual cell (cell number indicated for the first 7 cells to the left). Note that αMDG has an effect in \~40% of the cells. All data are represented as mean ± SEM.](EMS85189-f008){#F8}

![*a-b*, Changes in \[Ca^2+^\]~i~ in δ-cells exposed to 20mM glucose upon addition of dapagliflozin (12.5μM, highlighted by red rectangles) where the SGLT2 inhibitor either inhibits (a) or was without effect (b). 31 cells from 3 islets from 3 mice; dapagliflozin reduced Ca^2+^ oscillation frequency in 17/31 cells, and did not change Ca^2+^ oscillation frequency in the remaining 14/31 cells.](EMS85189-f009){#F9}

![*a*, The effects of dapagliflozin (1 μM) on the insulin-dependent potentiation of αMDG-induced increase in \[Na^+^\]~i~. All experiments measured in 1 mM glucose in the presence of 19 mM αMDG. Solid line represents representative insulin-responsive δ-cell. The dashed line represents an insulin-nonresponsive δ-cell. Data in *b* are mean values ± S.E.M. in of 88 dispersed δ-cells from 2 mice. Similar results were seen for a lower concentration of dapagliflozin (1 nM, see [Fig. 3e-f](#F3){ref-type="fig"}). 1-way RM ANOVA with Tukey's adjustment; \*p\<0.05 *vs*. no insulin or dapagliflozin, \#p\<0.05 *vs*. 100 nM insulin. All data are represented as mean ± SEM.](EMS85189-f010){#F10}

![*a*, Histograms summarising frequency of \[Ca^2+^\]~i~ oscillations at 1 mM glucose alone, following the addition of monensin and in the presence of monensin and a cocktail of isradipine (2.5 μM), SNX482 (100 nM) and diazoxide (100 μM) n= 53 cells from 3 islets/2 mice \*\*p\<0.005, one-way ANOVA followed by Tukey's post hoc for indicated comparisons. *b*, Membrane potential recordings from a δ-cell at 1 mM glucose in the absence and presence of monensin. Representative of 4 cells (n=3 mice). *c*, Effects of decreasing \[K^+^\]~o~ from the normal 3.6 mM to 1.7 mM. Note that the δ-cell is hyperpolarized at 1 mM glucose and not electrically active. Reducing \[K^+^\]~o~ leads to further hyperpolarization. *d*, Relationship between \[K^+^\]~o~ and membrane δ-cell potential. This relationship indicates that the membrane potential in δ-cells exposed to 1 mM glucose is principally (but not exclusively) determined by the K^+^ permeability (slope = 0.86 mV/mM). All data are represented as mean ± SEM.](EMS85189-f011){#F11}

![*a*, Average islet somatostatin content from non-diabetic and T2DM organ donors (n=17 non-diabetic (ND) and n=6 T2DM donors. *b*, Average islet glucagon content from non-diabetic and T2DM organ donors (n=41 non-diabetic and n=12 T2DM donors). Unpaired 2-sided t-test; \*\*\**P*\<0.001 *vs*. ND. In *a-b*, data for each donor was treated as one experiment. *c*, Membrane potential recording at 1, 6 and 20 mM glucose (indicated above membrane potential trace) from an α-cell identified by its low cell capacitance (2 pF) showing spontaneous action potential firing at 1 mM glucose. Representative of a total of 5 α-cell from 4 non-diabetic donors (3 cells were identified as α-cells by immunocytochemistry). *d*, As in (*c*) but measurements were made from an α-cell (identified by immunocytochemistry) in an islet from a donor with type 2 diabetes. Note that action potential firing is frequently interrupted by transient hyperpolarizations (arrows) and that these are almost abolished in the presence of CYN154806. Similar data were obtained from another 3 α-cells (identified by low cell capacitance and spontaneous action potential firing) from the same donor. Data represented as mean ± SEM.](EMS85189-f012){#F12}
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![Regulation of somatostatin secretion by Ca^2+^.\
*a*, Glucose-induced \[Ca^2+^\]~i~ oscillations in 3 representative δ-cells (n=79 cells from 7 mice). *b-c*, Somatostatin secretion (*b*) and frequency of \[Ca^2+^\]~i~ oscillations (*c*) measured at 1, 4 and 20 mM glucose (n=61-79 cells/7 islets/7 mice). 1-way ANOVA with Tukey adjustment. *d-g*, Frequency of \[Ca^2+^\]~i~ oscillations in the absence or presence of tolbutamide (*d*; n=48 cells/3 mice; 2-sided t-test), diazoxide (*e*; n=13 cells/3 mice, 1-way RM ANOVA with Tukey adjustment), isradipine (*f*; n=22 cells/3 mice, 1-way RM ANOVA with Tukey adjustment) and SNX482 (*g*; n=22 cells/3 mice, 1-way RM ANOVA with Tukey adjustment). \*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.001 vs 1 mM glucose; †††p\<0.001 vs 20 mM glucose. All data are represented as mean ± SEM.](EMS85189-f001){#F1}

![Insulin-induced intracellular Ca^2+^ mobilization.\
*a*, Parallel measurements of membrane potential (V~m~) and \[Ca^2+^\]~i~ in a δ-cell recorded at 1 and 10 mM glucose (representative of 4 experiments). Dotted vertical lines have been inserted to highlight the lack of correlation between V~m~ and \[Ca^2+^\]~i~. *b*, As in (*a*) but in a δ-cell voltage-clamped at -70 mV. Diazoxide was included as indicated (red). It was ascertained by application of a 500-ms voltage-clamp pulse from -70 to 0 mV (left) that the \[Ca^2+^\]~i~ measurements reflect the voltage-clamped cells (representative of 3 experiments). Scatter graph (inset) summarizes effects of 1 mM glucose (open circle), 20 mM glucose (open square) and 20 mM glucose with 100 μM diazoxide (open triangle) on \[Ca^2+^\]~i~ (AUC). 1-way RM ANOVA with Tukey adjustment, n=4 cells/3 mice. *c*, (Top): Bar graphs summarising the frequencies of \[Ca^2+^\]~i~ oscillations in the absence or presence of (*i*) insulin (Ins; 100 nM), (*ii*) urocortin-3 (UCN3; 100 nM) and (*iii*) insulin (100 nM), forskolin (3 μM) and dapagliflozin (100 nM: Ins+Fsk) all in the continued presence of 20 mM glucose and 100 μM diazoxide. 1-way RM ANOVA with Tukey adjustment; \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. The pie charts indicate the % of cells responding to each of these conditions (total number of cells are indicated; from 2-3 mice). *iv*, Insulin-induced \[Ca^2+^\]~i~ oscillations in the presence of forskolin and their suppression by dapagliflozin. *d*, Somatostatin secretion measured in the presence of glucose, diazoxide, insulin and dapagliflozin as indicated (n=5 experiments/3 mice). 1-way ANOVA with Tukey adjustment; \*\*\*p\<0.001 *vs*. 1 mM glucose; ††p\<0.01, †††p\<0.05, *vs*. 1 mM glucose. *e*, Somatostatin secretion (after normalization to somatostatin content) measured in control and SIRKO mice at 1 and 20 mM glucose in the absence and presence of dapagliflozin as indicated (n=5 experiments/3 mice). 1-way ANOVA with Tukey adjustment; \*p\<0.05, \*\*p\<0.01, †p\<0.05. *f*, Somatostatin secretion at 1 and 20 mM glucose (as indicated) and increasing concentrations of dapagliflozin (n=10 experiments/7 mice). The curve was derived by fitting the function y = base -- (base-min)/(1 + (x~50~/x)\^rate) to the mean values (base =2.5, min=1.4, x~50~ = 10 nM and rate=-1). *g*, Somatostatin secretion at 1 and 20 mM glucose and phlorizin (50 μM) as indicated (n=7-10 experiments/7 mice). 1-way ANOVA with Tukey adjustment; \*p\<0.05, \*\*p\<0.01 *vs*. 1 mM glucose; †p\<0.01 *vs*. 20 mM glucose. *h*, glucagon secretion in the presence of glucose, dapagliflozin and CYN154806 as indicated (n=6-9 experiments/3 mice). 1-way ANOVA with Tukey adjustment; \*\*\*p \<0.0005 *vs*. 1 mM glucose; ††p\<0.01 *vs*. 20 mM glucose; ‡‡p\<0.01 *vs*. 20 mM glucose with 12.5 μM dapagliflozin. *i*, Somatostatin secretion measured in the presence of glucose, αMDG and \[Na^+^\]~o~ as indicated (n=8 experiments/3 mice). 1-way ANOVA with Tukey adjustment; \*\*\*p \<0.0005 *vs*. 1 mM glucose; †p\<0.05, *vs*. 1 mM glucose with 19 mM αMDG and 140 mM \[Na^+^\]~o~; ‡‡‡p\<0.01 *vs*. 20 mM glucose with 140 mM \[Na^+^\]~o~. All data are represented as mean ± SEM.](EMS85189-f002){#F2}

![Elevation of cytoplasmic Na^+^ stimulates somatostatin release.\
*a*, Effects of αMDG applied at 1 mM glucose on δ-cell \[Ca^2+^\]~i~ and impact of lowering \[Na^+^\]~o~ as indicated (72 of 182 cells in 8 islets from 6 mice). *b*, As in (*a*) but αMDG applied in islets pretreated for 90 min with thapsigargin (oscillations observed in 4 of 34 cells in 3 islets from 3 mice). *c*, Effects of αMDG on \[Na^+^\]~i~ measured in dispersed δ-cells applied at 1 mM glucose in the absence and presence of 100 nM dapagliflozin (Dapa) as indicated. Trace representative of αMDG-responding δ-cells (53 of 136 cells). The fluorescence (F) has been normalised to the initial signal (F~0~) in the subset of cells responding to αMDG. *d*, Bar graph summarising effects of αMDG and dapagliflozin on \[Na^+^\]~i~. Mean values ± S.E.M. in 53 of 136 cells from 4 mice (only the subset of cells responding to αMDG were included in these analyses). \*p\<0.05. *e-f*, As in *c-d* but in the presence of 100 nM insulin and 1 nM dapagliflozin (Dapa). The dotted line shows data for insulin-unresponsive cells. Data in *f* are mean values ± S.E.M. in of 36 insulin-responsive δ-cells from 2 mice. *g*, \[Ca^2+^\]~i~ measured in a δ-cell induced by monensin (50 μM) applied at 1 mM glucose and lack of effects of a cocktail of diazoxide (0.1 mM), SNX482 (100 nM) and isradipine (2.5 μM) (shaded area). *h*, Plasma K^+^ measured in mice before and 45 min after intraperitoneal injection of 0.75 U/kg body weight insulin. Paired t-test; \*p\<0.05 (n=5 mice). Plasma glucose fell from 7.4±0.6 to 3.7±0.7 mM (n=5 mice). *i-j*, As in *c-d* but measuring the effect of lowering \[K^+^\]~o~ from 4.7 to 2.7 mM. Bar graph in (*j*) shows mean value ± S.E.M of 231 cells from 4 mice. All cells were included in this analysis. Paired t-test; \*\*\*p\<0.001. *k*, \[Ca^2+^\]~i~ oscillations induced at 1 mM glucose by lowering \[K^+^\]~o~ to 2.7 mM (representative of 16 cells in 3 islets from 2 mice). All data are represented as mean ± SEM.](EMS85189-f003){#F3}

![Effects of hypokalaemia and type-2 diabetes on glucagon and somatostatin secretion.\
*a-b*, Somatostatin (*a*) and glucagon secretion (*b*) at 1 mM (black) and 6 mM (red) glucose at the indicated \[K^+^\]~o~. 1-way ANOVA with Tukey adjustment; †p\<0.05; ††p\<0.01; †††p\<0.001 *vs*. 1 mM glucose at 4.7 mM \[K^+^\]~o~. Effects of increasing glucose from 1 to 6 mM is statistically significant at 4.7, 3.7 and 2.7 mM \[K^+^\]~o~; \*p\<0.05; \*\*p\<0.01 and \*\*\*p\<0.001. Mean values ± S.E.M of n=12 experiments/6 mice. *c*, Glucagon secretion at 1 or 6 mM glucose and at 4.7 or 1.7 mM \[K^+^\]~o~ in the absence or presence of CYN154806 (CYN) as indicated. 1-way ANOVA with Tukey adjustment; \*\*\*p\<0.001 *vs*. 1 mM glucose at 4.7 mM \[K^+^\]~o~; †††p\<0.001 *vs*. 1 mM glucose at 1.7 mM \[K^+^\]~o~; ‡‡p\<0.005 *vs*. 1 mM glucose at 1.7 mM \[K^+^\]~o~ in the presence of CYN154806 (n=9 experiments/4 mice). *d*, Somatostatin secretion in islets from control (CTL) and hyperglycaemic Fh1βKO (KO) mice at 1 and 20 mM glucose (n=4-5 using islets from 4 mice). 1-way ANOVA with Tukey adjustment; \*\*p\<0.01 vs 1 mM glucose; †p\<0.05 *vs*. 1 mM glucose in CTL islets. *e*, Glucagon secretion from the perfused mouse pancreas of CTL (n=5) and hyperglycaemic Fh1βKO (KO, n=4) mice at 1 mM glucose in the absence and presence of CYN154806 as indicated. 1-way ANOVA with Tukey adjustment; \*p\<0.05 for the effect of CYN154806; †p\<0.05 for difference between Fh1βKO and wild-type pancreases at 1 mM glucose. *f*, Somatostatin secretion at 1 and 20 mM glucose in islets from non-diabetic (ND, n=32 donors) and type-2 diabetic donors (T2DM, n=7 donors). 1-way ANOVA with Tukey adjustment; \*\*\*p\<0.001 *vs*. 1 mM glucose. ns (not significant), p=0.57. *g*, Glucagon secretion measured at 1 mM glucose in islets from ND (n=50 donors) and T2DM donors (n=12 donors). 1-way ANOVA with Tukey adjustment; \*p\<0.05, \*\*p\<0.01 *vs*. 1 mM; †p\<0.05 *vs*. ND. *h*, Effect of the SSTR2 antagonist CYN154806 on glucagon secretion in islet preparations from three donors with T2D. Note that CYN154806 increases glucagon secretion in the two preparations with low glucagon secretion and that it had no effect on the preparation with high glucagon secretion. The shaded area and superimposed black line indicate glucagon secretion at 1 mM glucose in islets from non-diabetic donors (mean secretion ± S.E.M. in 41 preparations). *i*, Schematic summarising the stimulus-secretion coupling in δ-cell. Glucose uptake (via GLUT1 or 3) leads to stimulation of glucose metabolism (glycolysis and mitochondria) and an increased cytoplasmic ATP/ADP ratio. This closes K~ATP~ channels in the plasma membrane, producing membrane depolarization and activation of voltage-gated Ca^2+^ channels (VGCC). Ca^2+^ influx associated with electrical activity triggers further increase in cytoplasmic Ca^2+^ (\[Ca^2+^\]~i~) by Ca^2+^-induced Ca^2+^ release (CICR) in the sarco/endoplasmic reticulum (sER) by activation of ryanodine receptor 3 (RyR3) Ca^2+^ release channels. The resultant increase in \[Ca^2+^\]~i~ triggers somatostatin secretion. Inhibitors of the Ca^2+^ ATPase ('Ca^2+^ pump') of the sER (SERCA inhibitors; e.g. thapsigargin) inhibit somatostatin secretion by depleting sER of Ca^2+^. Glucose also stimulates somatostatin secretion by elevation of intracellular Na^+^ (\[Na^+^\]~i~) (possibly mediated by SGLTs) and thereby increases \[Ca^2+^\]~i~ via stimulation of *intra*cellular Na^+^-Ca^2+^ exchange (NCLX) and thereby triggers CICR independently of electrical activity. Inhibition of the Na^+^/K^+^ ATPase (by low \[K^+^\]~o~) also increases \[Na^+^\]~i~ and triggers CICR.](EMS85189-f004){#F4}
